DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet therapy regimen shows significant improvement in outcomes for patients with transplant-eligible newly diagnosed multiple myeloma ...Middle East

DARZALEX FASPRO®-based induction, consolidation and maintenance regimen reduced risk of progression or death by 58 percent compared to standard of care regimen First presentation of data from Phase 3 PERSEUS study highlighted in late-breaking abstract session at ASH 2023 and...

Hence then, the article about darzalex faspro daratumumab and hyaluronidase fihj based quadruplet therapy regimen shows significant improvement in outcomes for patients with transplant eligible newly diagnosed multiple myeloma was published today ( Tuesday 12/12/2023 - 08:12 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet therapy regimen shows significant improvement in outcomes for patients with transplant-eligible newly diagnosed multiple myeloma )

Also on site :

• Hiring, overtime, and AI: VA is Processing veterans’ disability claims faster than ever
• Karoline Leavitt Melts Hearts With Mother’s Day Photo of Her Newborn Daughter and Toddler Son Snuggling
• Trump vows to get Iran’s enriched uranium